Website: ellisbio.com   |   LinkedIn: linkedin.com/company/ellis-bio/

Gentler Chemistry, Better Methylation Data

How Ellis Bio is turning Nobel-caliber epigenetics research from the University of Chicago into tools every lab can use

At a glance

  • Company: Ellis Bio (ellisbio.com)
  • Origins: Spun out of The University of Chicago, with scientific founder Professor Chuan He
  • Focus: Next-generation epigenomics tools for DNA methylation analysis, biomarker discovery, and diagnostics research
  • Products: SuperMethyl™ bisulfite conversion kits
  • Working with PSG on: HubSpot, marketing, sales and business development scaling, fractional Commercial leadership

From the lab of a pioneer

Ellis Bio takes its name from Ellis Avenue, which runs past several of the University of Chicago’s leading research labs, including that of Professor Chuan He. A Howard Hughes Medical Institute Investigator and Wolf Prize laureate in Chemistry, Professor He is one of the world’s foremost scientists in epigenetics and epitranscriptomics, the chemical modifications on DNA and RNA that control how genes are expressed.

Ellis Bio exists to move those discoveries out of the academic lab and into the hands of researchers everywhere.

The problem with bisulfite

DNA methylation is one of the most powerful biomarkers for disease diagnosis and prognosis, especially in early cancer detection. But the standard method for reading it, bisulfite conversion, is harsh. It damages and degrades DNA, which is a serious problem when samples are tiny or precious, like cell-free DNA from a blood draw.

SuperMethyl™: high accuracy, minimal damage

  • SuperMethyl™ Max is built on Ultra-Mild Bisulfite Sequencing (UMBS), a method developed in Professor He’s lab and exclusively licensed to Ellis Bio worldwide. It delivers highly accurate methylation profiling from as little as 100 pg of DNA, with high recovery, minimal degradation, and NGS compatibility
  • SuperMethyl™ Flash is Ellis Bio’s first kit, designed to speed up methylation workflows

SuperMethyl™ Max launched commercially at AGBT 2026 after an early-access debut at ADLM 2025. It’s available worldwide through distribution partners including Eagle Biosciences (US), PELOBiotech (EU), Stratech Scientific (UK), and AS ONE (Japan).